solid label await clariti launch strategi
earn preview bj kr still need
color fundament focu call hd
reblozyl track md approv look ward
sotatercept full pah reveal at
solid ruc code expect juli compani expect
updat featur major catalyst
updat pivot melanoma data horizon
analyst certif import disclosur see
updat move closer in-vivo crispr
focu pipelin
solid quarter mind macro
review strong invest setup beyond
growth back-end weight prove value-add
busi acceler look glide
path rule
workday financi busi close strong
strong street revenu guid
solid result prepar addit growth
earnings/profit trajectori improv take advantag
nii miss despit strong flow remain
anoth stabl quarter close
solid label await clariti launch strategi
announc approv nurtec-odt rimegep acut treatment migrain believ compani obtain
strong label differenti nurtec-odt anoth approv oral cgrp-receptor antagonist ubrelvi see exhibit
full report publish today anticip launch earli march revenu reach peak
report key item label await updat manag launch strategi
downgrad solid wast sector view broad-bas commod headwind soften medium-term
indic high absolut rel valuat concern regard commod headwind sinc diminish
results/commentari earn recent meet wm link wcn link suggest healthi near-term
solid wast fundament recent long-term indic hous cpi increment posit though soften
indic could occur march howev detail report recession-resist solid wast
econom weak transpir expect wast fundament outperform industri benchmark strength
price disciplin margin resili healthi gener opportunist wast valuat remain elev
believ reflect low-yield environ lower risk signific downsid estim revis rel
broader market particularli next quarter upgrad share wm wcn outperform
marvel report earn wednesday see jan result line consensu sales/ep
importantli expect modest downsid bia apr consensu reflect coronaviru impact
reduc ep estimate increas juli oct est leav ep
unchang see coronaviru drag impact entir semi group near term though pent-up demand boost
outlook expect storag segment continu recoveri toward prior run rate year network
begin see initi benefit earli stage macro bt deploy top infrastructur play
view structur growth thesi intact remain long-term buyer
earn preview bj kr still need select
ahead earn next week spent time updat view bj kr see risk bj deliveri
slightli consensu guid bj kr expect larg in-lin quarter reiter
guidanc final fundament momentum busi remain strong compani lap
oner ga comparison street could mismodel prior year benefit believ well-understood
market nonetheless would take advantag potenti weak comparison relat shortfal
volatil market late pleas see upgrad titl recent under-perform creat attract entri point
latest think dg remain top pick within food retailing/ discount coverag
bj kr remain radar exhibit today earn preview summari estim price
analyz variou competit offer energi storag system solar space examin compar
configur price quality/function pwrcell seemingli offer optim scalability/pr relationship
lead lead metric round-trip effici continu power output surg power possibl compar shortfal
rel one two competitor noth univers tell includ potenti less optim case
exist solar instal increment invest technic compat also direct effici trade-off
favor pwrcell rel efficaci complex multi-dimension solar array materi anyth
expect deploy hour storag capac base order backlog partner indic
requisit suppli measur basi substanti splash
color fundament focu call hd
thursday allogen report result discuss progress manag allogen track deliv
first result alpha trial trial respect expect
alpha result includ preliminari outcom patient enrol dose escal cohort receiv vari
lymphodeplet regimen result could inform lymphodeplet strategi allogen intend
advanc trial slate initi accommod phase dose escal portion
ad six month overal develop timelin nhl rel previou estim believ allogen
oper runway cover multipl de-risk clinic readout reiter outperform pt
reblozyl track md approv look ward sotatercept full pah reveal at
net loss came estim higher vs reblozyl luspatercept
earli phase us commerci transfusion-depend -thalassemia partner qualit launch
commentari favor modest indic patient anticip approv much greater md
opportun april base solid medalist result detail pulsar data sotatercept pah showcas
at may follow impress top-lin next month phase readout charcot-marie-tooth may yield
upsid surpris view core biotech hold reiter outperform
solid ruc code expect juli compani expect unchang
irhythm report rev y/i roughli line pre-announce our/consensu
estim impact reserv non-contract rev mix rise patient co-pays/deduct
delay return cc gross margin consensu opex well
estim revis bonu adjust consult process
store new store sale back eagerli await cmss final rvu determin expect juli statu quo
rate would facilit construct stanc part rate cut would bode well stori meantim
twiddl thumb
updat featur major catalyst
deliv solid financi result financi guidanc near-term catalyst ep slightli
beat consensu estim driven nuplazid net sale
consensu estim guidanc nuplazid net sale reflect growth y/i midpoint
estim also guid higher opex support four pivot studi drp launch prepar note
major near-term catalyst includ drp snda file potenti approv mdd
readout nss initi trofinetid lavend rett syndrom readout
bd remain prioriti cash full report date detail
updat pivot melanoma data horizon
nektar report financi result guidanc provid pipelin updat sever promis
early-stag asset other think investor mostli focus bempeg combo
trial checkpoint inhibitor especi onzeald gone amend collabor includ
five three prior registr nivo bempeg trial ad adjuv melanoma muscle-invas bladder cancer
initi nsclc nivo bempeg trial data led breakthrough therapi design melanoma
endpoint includ orr os potenti cr orr basi acceler approv could report
mpf six month later bempeg follow-up present orr
mpf reach
share sag vs nbi commentari around zuranolon develop option
manag highlight sever near-term pipelin catalyst includ zuranolon fda meet evalu
regulatori path forward base mountain learn shorelin read-out late
longer half-lif gaba-a pam et anticip initi trial nmda pam result
demonstr improv cognit function hd patient clean safeti plan initi studi
zulresso sale vs consensu guid modest revenu growth uptick
updat model actual drive new
ortx report result provid busi updat includ discuss commerci prepar ahead
ema regulatori action metachromat leukodystrophi mld eu commerci
team establish manag near-term object includ build diseas awar improv access
diagnost test establish manufactur suppli chain infrastructur qualifi treatment center initi market
access discuss increas estim probabl approv ou us anticip
launch late gradual eu uptak given broad pipelin near-term regulatori catalyst continu
execut believ ortx offer attract invest opportun increas price target
maintain outperform thesi
focu pipelin
report full-year result today provid busi updat includ near-term commerci research prioriti
anticip continu revenu growth gbm uptak mesothelioma note key near-term catalyst
interim readout phase lunar trial nonsmal cell lung cancer nsclc estim valuat assum trial
continu post interim analysi separ like strong balanc sheet potenti grow oper cash flow
manag continu invest pipelin technolog expand commerci maintain outperform rate
price target vs previous
host key opinion leader ind investig new drug file transcript/replay avail dr bhardwaj
desai discuss build block differ therapeut areas/mod pre-ind ind file discuss stay
focus around three broad area ind applic entail anim pk toxicolog studi chemistri manufactur
control clinic protocols/interact fda walk away call sever takeaway
time taken reach ind-fil highli variabl depend variou factor preclin anim toxicolog efficaci
model critic matter ind-fil also way nda/post-market manufactur critic
area new modal gene therapi rna etc red flag safeti side mostli concern anim toxicolog
batch consist scalabl
updat move closer in-vivo crispr
report result collabor revenu opex cash balanc manag
estim fund oper make progress in-vivo edit ex-vivo engin t-cell
remain track nda submiss attr trial design unveil later lowest sad
dose therapeut rang initi patient may soc non-respond nomin tcr
program candid present data product homogen tgtcr chain pair trac insert
trbc ko activ patient-deriv aml blast ind file expect liver front
present prekallikrein ko strategi hereditari angioedema
addu announc delay earn releas origin schedul order allow compani addit
time complet valuat non-cash implicit price concess relat revenu account receiv includ
period relat perform relat intern control assess compani went say
delay due use new independ auditor base convers manag would
jump conclus resultsth compani report vagu annual revenu growth metrica delay
appear larg procedur natur also chang estim time
report adj ep vs opco/street consensu estim though
beat aid tax benefit result also impact neg one-tim factor pdgm case-mix etc
growth trend appear robust issu ep guidanc opco/street
opco/street prior expect lightest year due early-year impact
pdgm tweak estim maintain estim
believ long-term opportun remain on-track overal believ stock sell-off overreact
would use opportun buyer
report good result assess posit includ good contribut digit construct
replatform opportun expand oper margin strong free cash flow gener balanc guidanc
soft partial attribut current instabl macro environ season manag longer
give guidanc may take time investor gain comfort bottom line guid take
account macro disrupt futur growth cash flow gener assum stabil versu worsen macro
think rais risk estim given level uncertainti magnitud potenti global disrupt caus
thu remain sidelin maintain perform
solid quarter mind macro
pure deliv solid year-end includ strong enterpris demand healthi new custom activ though
guidanc expect reflect normal season macro headwind faster plan
adopt subscript servic howev take account potenti impact viru
leav addit downsid risk take conserv view model manag guidanc
said comfort outperform rate long-term see posit pure steadi new custom activ
competit posit fast-pac product/us case expans adapt incorpor subscript servic
review strong invest setup beyond
follow year-end financi result set stage entail breadth activ
across clinic regulatori pre- commerci activ pegcetacoplan spite pullback sector-
wide sentiment market weak believ invest setup bode well
manag stay focus regulatori commerci activ pegcetacoplan pnh on-going
execut phase ga studi prime pivot clinic readout ga thu earli period pnh
launch could dovetail nice clinic ga catalyst readout ahead strong setup includ pipelin
option aiha updat model stay bullish
report solid result consist recent pre-announc ebitda reflect y/i
margin expans target organ macro-adjust growth acceler remain challeng although
anticip improv guidanc consist recent pre-announc assum
organ revenu growth benefit low interest rate relat strong mortgag volum appreci
sinc earli novemb includ ytd vs ebitda meaning chang
ebitda multipl increas view reason attract accordingli
downgrad perform remov pt howev preclud outperform near-term given invers
growth back-end weight prove value-add digit marketplac
maintain target outperform rate despit guidanc slower organ growth ftch deliv strong
surprisingli upbeat coronaviru impact overal see ftch digit platform stori succeed
challeng time luxuri retail digit platform gmv y/i vs digit platform gmv y/i
organ revenu vs digit platform order contribut y/i vs margin modestli
q/q y/i brand partner mix guidanc impli organ gmv digit platform gmv slower
growth management reiter ebitda break-even assum digit platform revenu grow
cloud
acceler revenu growth solid margin expans take share internet report highest
revenu growth eight quarter last quarter expect volum acceler
new ott video services/gaming/olymp drive growth cloud adopt ott servic secular
driver drive demand cecoi low cost internet transit servic neg compani trade
three turn highest ebitda multipl ever dividend attract abil grow plu per year
next five year regard rais dividend growth previous
analyt collabor infrastructur softwar
vmware deliv mix quarter finish fiscal year initi outlook reflect sale execut issu higher
mix subscript saa revenu initi view potenti neg impact viru although
result outlook disappoint potenti limit near-term upsid believ acceler mix
shift subscript saa includ licens revenue rise portfolio breadth carbon black pivot
upcom project tanzu bode well long term offer path solid growth margin expans higher multipl
investor weigh grow contribut subscription/saa product adjust estim results/guid recast
histor pivot pt remain maintain outperform
coronaviru cloud timelin new iphon reuter
suppli chain set breach shipment contract amid outbreak digitim
server sector may see compon shortag outbreak continu digitim
test chines cpu deep dive zen-bas hygon dhyana processor anand
busi acceler look glide path rule
consist preview highlight strong overal buy environ special event tailwind
busi report consensu result meaning revenu ebitda growth despit tough comparison
addit manag like surpris street guid gross spend acceler contrast
industri experienc deceler spend suggest share gain balanc outlook impli
busi slowdown despit easier comparison could prove conserv bottom line acceler stori
reflect valuat multipl financi guidanc see sever catalyst special event cyclic pick-
europ ramp larg msa connect tv adopt came could drive faster growth
workday financi busi close strong momentum
workday deliv solid result result suggest financi busi exit strong momentum
balanc outlook point growth slowdown despit easier year/year comparison could
prove conserv given financi busi momentum bottom line posit share year given
thesi workday financi momentum still earli day play within compani instal base
overal market result lend support workday manag plan analyt product
provid growth tailwind next month busi newer product initi cloud platform
industri procur look good futur growth catalyst reiter outperform target
emerg technolog servic
axon slowli build eco-system polic agenc deliv flywheel effect revenu offic
advanc taser connect body/dash camera sensor hardwar respond quickli emerg call
command center agent quickli grab inform remot intern rm provid offic
ground situat awar allow offic quickli safe de-escal situat follow
intuit ai-driven record writer individu piec worth nearli whole even train hire new offic
requir new approachaxon axon get year hardwar year softwar
strong street revenu guid high expect setup
look favor upon bynd deliveri upbeat initi guid revenu easili top street
expect even ramp competit initi revenu guid also ahead consensu forecast
come ahead street figur compani clearli see momentum domest oper
retail foodservic appear increasingli focus drive growth intern market us valuat
continu remain biggest roadblock recommend share level competit also remain concern
commentari call suggest limit impact date share after-market close believ
reflect high expect print follow mcd specul
sustain growth resourc optim
solid result prepar addit growth
share may see short-term pressur growth low end expect commentari
compani would like refin fewer asset vs believ compani make import invest
process standard optim anticip effort precursor effici acceler growth
beyond continu believ system instal qualiti perform critic underwrit term expect
credit market continu reward low interest rate high ltv ratio also look
increment traction storag product abil monet asset ancillari servic market remain
bullish would buyer weak
deliv solid close via adjust ep y/i exceed estimate/consensu
respect continu demonstr initi step forward within five key strateg focu prioriti
qualiti revenue/oper cost efficiencies/erp implementation/portfolio rationalization/debt restructur leverag
improv quality-of-revenu initi drove core regul wast complianc servic segment organ
growth y/i highest rate three year compani also focus sg expens reduct advanc
erp implement decemb agre sale oper chile februari domest
environment solut loke ahead organ guidanc impli y/i improv free cash flow
gener well adjust ebitda/ep
earnings/profit trajectori improv take advantag recent market volatil
report ep vs our/consensu upbeat time given
market recent perform improv eps/profit trajectori depress valuat investor look
alpha may decid prudent invest near-term long-term take advantag eu competitor
de-lever thu put record level eu purchas like continu yet temper eu
purchas vs leav upsid collect rate start improv recent vintag relat legal
strategi hone expertis cost-to-collect improv yoy better collector product look ahead today could
good entri point start posit yet wait end us suppli acceler
nii miss despit strong flow remain sidelin
long believ leon black dictum one creat valu invest decis embrac
complex believ clo equiti asset class time remain sidelin ecc
share result wit anoth declin although nice novemb bottom net invest
incom nii short expect alreadi quarterli distribut rate
good news gross cash flow clo seem stabl quarter vs last quarter
gross cash flow combin invest incom return capit unclear us sustain
anoth stabl quarter close
nmfc steadili close gener adjust net invest incom nii ahead
estim cover dividend consecut quarter adjust nii
interest incom incent fee relat ppva fund per quarter revenu impact appear manag
nmfc one stabl predict bdc cover earn averag dividend
expect trend continu continu see nmfc qualiti core hold sector reiter
outperform rate price target togeth yield look total expect return
month
may biotech summit featur chemistri life process institut chicago il
juli montauk summit emerg life scienc montauk ny
